An experimental drug appears to reduce the risk of Alzheimer's-related dementia in people destined to develop the disease in their 30s, 40s or 50s, according to the results of a new study. The ...

An experimental drug appears to reduce the risk of Alzheimer’s in people “destined” to develop the disease in middle age. For 22 patients who had no cognitive problems at the start of the ...

Eli Lilly (LLY) stock in focus as an expert panel of the EU drug regulator declines to endorse its Alzheimer's drug Kisunla.

For people who discover they carry genetic mutations that virtually guarantee they will develop Alzheimer’s disease ... the experimental anti-amyloid drug for an average of eight years, with ...

But new research on an experimental drug suggests that it could potentially help lower the odds of developing Alzheimer's in people who are genetically predisposed to the devastating condition.

An experimental drug appears to reduce the risk of Alzheimer’s in people “destined” to develop the disease in middle age. The study, published in the journal The Lancet Neurology, involved 73 people ...

Get Instant Summarized Text (Gist) Common drug combinations affect Alzheimer's disease progression differently in male and female mice. A five-drug combination improved memory and reduced ...

For the first time, scientists say they have evidence that a drug might delay the onset of Alzheimer’s symptoms in people who are genetically predisposed to getting the disease in their 40s or 50s.

Published in the Lancet Neurology journal, a new study found increased doses and long-term use of the drug could delay the onset of Alzheimer's symptoms for those with a genetic form of the disease.

Lecanemab, an Alzheimer's-modifying drug, has shown a 27% reduction in cognitive decline overall in its Phase 3 trial. However, data indicates it may be less effective in females, though not ...

Researchers studying Alzheimer’s disease are using artificial intelligence-powered databases to accelerate the drug discovery process by making it easier to sift through vast amounts of ...

Cassava Sciences (SAVA) stock falls as the company halts Alzheimer's drug program after trial failures. Read more here.